Liminatus Pharma, Inc. — Form SCHEDULE 13D/A
Filed July 14, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Valetudo Therapeutics LLC and Chris Kim (CEO) executed a joint filing agreement on July 14, 2026, to file a Schedule 13D amendment regarding Liminatus Pharma securities. The filing documents their coordination in disclosing beneficial ownership changes, but the actual ownership stake, dollar amounts, and share counts are not specified in this exhibit—only the procedural agreement itself is shown.
Why this rating
Joint filing agreement is procedural boilerplate. Ownership details missing; cannot assess materiality without knowing stake size relative to $221M market cap.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.